EPP449 - Vortioxetine monotherapy for treatment-resistant OCD: evidence from a retrospective multicentre study
EPP449
Vortioxetine monotherapy for treatment-resistant OCD: evidence from a retrospective multicentre study
V. Martiadis 1, F. Raffone 1,*, S. Testa 1, C. Iaccarino 1, E. Pessina 2, A. Martini 2, T. Prodi 3, M. Olivola 3, C. I. Cattaneo 4, D. De Berardis 5, B. Benatti 3 6, B. M. Dell'Osso 3 6 7 8
1Department of Mental Health, Asl Napoli 1 Centro, Naples, 2Department of Mental Health, Asl Cuneo 2, Bra, 3Department of Biomedical and Clinical Sciences Luigi Sacco, Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, 4Department of Mental Health, Asl Biella, Naples, 5Department of Mental Health, Asl Teramo, Teramo, Italy, 6Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford Medical School, Stanford University, Stanford, United States, 7CRC 'Aldo Ravelli' for Neurotechnology & Experimental Brain Therapeutics, 8Centro per lo Studio dei Meccanismi Molecolari alla base delle Patologie neuro-psico-geriatriche, University of Milan, Milan, Italy
Introduction: Obsessive-compulsive disorder (OCD) resistant to selective serotonin reuptake inhibitors (SSRIs) remains a major clinical challenge, as many patients do not adequately respond to first-line treatments. Vortioxetine, a multimodal antidepressant approved for major depressive disorder, shows a favorable tolerability profile and potential cognitive benefits. However, evidence for its use in OCD is limited.
Objectives: This study evaluated the efficacy and tolerability of vortioxetine monotherapy in adults with SSRI-resistant OCD.
Methods: This retrospective, observational, multicentre study included 64 adults with OCD (DSM-5) who had not responded to at least one adequate SSRI trial (≥12 weeks, therapeutic dose). Patients received vortioxetine monotherapy (≥20 mg/day) for at least eight weeks. Symptom severity was measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A) at baseline and weeks 2, 4, 6, and 8. Clinical response was defined as a ≥25% reduction in Y-BOCS. Adverse events were systematically recorded.
Results: At week 8, 39.1% of patients achieved response. Mean Y-BOCS scores decreased from 27.1 to 20.7 (p<0.001), with improvements in both obsessions and compulsions. HAM-D and HAM-A scores also significantly decreased (p<0.001), from 21.0 to 12.6 and 26.9 to 16.1, respectively. Vortioxetine was generally well tolerated; 59.4% reported at least one side effect, most commonly nausea (29.7%). No serious adverse events were observed.
Conclusions: These findings suggest vortioxetine monotherapy may be a promising and safe option for SSRI-resistant OCD. Controlled, prospective studies are needed to confirm its role in this population.
Disclosure of Interest: None Declared